Reaktionsgleichung
[C:1]([N:4]1[CH2:8][CH2:7][N:6]([C:9]2[CH:14]=[C:13](Cl)[CH:12]=[CH:11][C:10]=2[C:16]([N:18]2[CH2:23][CH2:22][N:21]([C:24]3[C:29]([CH3:30])=[CH:28][C:27]([CH3:31])=[CH:26][N:25]=3)[CH2:20][CH2:19]2)=[O:17])[C:5]1=[O:32])(=[O:3])[CH3:2].[CH3:33][C:34]1([CH3:40])[O:38][C:37](=[O:39])[N:36]=[CH:35]1>>[C:1]([N:4]1[CH2:8][CH2:7][N:6]([C:9]2[CH:14]=[C:13]([N:36]3[CH2:35][C:34]([CH3:40])([CH3:33])[O:38][C:37]3=[O:39])[CH:12]=[CH:11][C:10]=2[C:16]([N:18]2[CH2:23][CH2:22][N:21]([C:24]3[C:29]([CH3:30])=[CH:28][C:27]([CH3:31])=[CH:26][N:25]=3)[CH2:20][CH2:19]2)=[O:17])[C:5]1=[O:32])(=[O:3])[CH3:2]Komponenten
3
Edukt 2
Produkt 1
Versuchsvorschrift
By reaction and treatment in the same manner as in Example 201 and using 1-acetyl-3-{5-chloro-2-[4-(3,5-dimethylpyridin-2-yl)piperazine-1-carbonyl]phenyl}imidazolidin-2-one (653 mg) described in Preparation Example 126 and 5,5-dimethyloxazolin-2-one (165 mg) described in Preparation Example 43, the title compound (86.5 mg) was obtained.
Aufarbeitung
- customBy reaction and treatment in the same manner as in Example 201
- customdescribed in Preparation Example 43
Quellen und Nachweise
- ORD-Eintrag
- ord-f5f36e47716a4a65bbcfb41ab8c4e73f
- Quelldatensatz
- uspto-grants-2013_01
- Patentnummer
- US08354401B2
Verknüpfte Notizen
Wird geladen…